Presentation is loading. Please wait.

Presentation is loading. Please wait.

Study design (A) and subject disposition (B).

Similar presentations


Presentation on theme: "Study design (A) and subject disposition (B)."— Presentation transcript:

1 Study design (A) and subject disposition (B).
Study design (A) and subject disposition (B). (A) Subjects were stratified based on maintenance macrolide usage and randomised 2:2:2:1 to receive twice daily: 32.5 mg ciprofloxacin DPI (corresponding to 50 mg dry powder); placebo corresponding to 32.5 mg ciprofloxacin DPI; 48.75 mg ciprofloxacin DPI (corresponding to 75 mg dry powder); or placebo corresponding to 48.75 mg ciprofloxacin DPI for 29 days (±1 day). DPI, dry powder for inhalation; EOT, end of treatment. (B) A total of 288 patients were randomised. Of these, 286 received either study drug or placebo, and were included in both the ITT and safety analyses sets. ITT, intent-to-treat. Henry L Dorkin et al. BMJ Open Resp Res 2015;2:e000100 ©2015 by British Thoracic Society


Download ppt "Study design (A) and subject disposition (B)."

Similar presentations


Ads by Google